Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
P/E Ratio
--
P/B Ratio
1.66
Industry P/E
--
Debt to Equity
0.36
ROE
-2.49 %
ROCE
-149.33 %
Div. Yield
0 %
Book Value
1.87
EPS
-3.94
CFO
$-78.55 Mln
EBITDA
$-99.57 Mln
Net Profit
$-93.36 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Soligenix (SNGX)
| -23.19 | -8.81 | -16.87 | -68.83 | -74.36 | -64.17 | -53.30 |
|
BSE Sensex*
| 2.69 | 3.80 | 5.86 | 8.98 | 11.79 | 20.13 | 11.36 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Soligenix (SNGX)
| -77.56 | -88.79 | -31.75 | -48.44 | -11.72 | 68.60 | -61.05 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions.... The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy that is in Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942 and SGX945, an innate defense regulator technology for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in Behçet's disease; and SGX302, an IDR technology which is in Phase IIa study to treat mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate; SGX943, a therapeutic candidate for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Address: 29 Emmons Drive, Princeton, NJ, United States, 08540 Read more
Chairman of the Board of Directors, CEO & President
Dr. Christopher J. Schaber Ph.D.
Chairman of the Board of Directors, CEO & President
Dr. Christopher J. Schaber Ph.D.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Soligenix Inc (SNGX) stood at $ 9 Mln as on 31-Dec-24
The share price of Soligenix Inc (SNGX) is $2.07 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Soligenix Inc (SNGX) has given a return of -74.36% in the last 3 years.
Soligenix Inc (SNGX) has a market capitalisation of $ 7 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Soligenix Inc (SNGX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Soligenix Inc (SNGX) and enter the required number of quantities and click on buy to purchase the shares of Soligenix Inc (SNGX).
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy that is in Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942 and SGX945, an innate defense regulator technology for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in Behçet's disease; and SGX302, an IDR technology which is in Phase IIa study to treat mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate; SGX943, a therapeutic candidate for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Address: 29 Emmons Drive, Princeton, NJ, United States, 08540
The CEO & director of Dr. Christopher J. Schaber Ph.D.. is Soligenix Inc (SNGX), and CFO & Sr. VP is Dr. Christopher J. Schaber Ph.D..
There is no promoter pledging in Soligenix Inc (SNGX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Soligenix Inc. (SNGX) | Ratios |
|---|---|
|
Return on equity(%)
|
-261.3
|
|
Operating margin(%)
|
-7088.59
|
|
Net Margin(%)
|
-7267.84
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Soligenix Inc (SNGX) was $0 Mln.
$-0.10
(
